Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
School of Medicine, Tsinghua University, Beijing, China.
Clin Exp Rheumatol. 2022 Sep;40(9):1650-1656. doi: 10.55563/clinexprheumatol/ixcj8a. Epub 2022 Apr 20.
The aim of this study was to investigate the clinical features and outcomes of systemic lupus erythematosus (SLE) with myocarditis.
A retrospective study was conducted in all inpatients diagnosed with SLE and concurrent lupus myocarditis (LM) at Peking Union Medical College Hospital (PUMCH) from July 2013 to July 2019. The case group included patients with LM while patients in the control group were enrolled randomly at a ratio of 1:1 and age- and year-matched SLE patients without myocarditis during the same period. Clinical characteristics and outcomes of LM patients were collected.
Among 4719 SLE patients hospitalized to PUMCH over the 6-year period, 79 (1.67%) were diagnosed with LM, with a mean age of 32.38 ± 13.55 years and 89% were female. 52 (66%) cases presented abnormal ventricular wall motion function, and 30 (38%) cases showed a decreased left ventricular ejection fraction (LVEF) (<50%) in echocardiography. 10 (13%) LM patients died during hospitalisation. For risk factors of myocarditis, patients in the LM group had higher percentage of on neurological involvement, higher SLE disease activity index 2000 (SLEDAI-2K) scores, and higher rates of positive anti-nucleosome antibodies compared with the control group. Multivariate logistic regression demonstrated that low levels of C3 and high SLEDAI-2K scores were the independent risk factors for developing LM in SLE patients (OR=0.870, 95%CI 0.762-0.994, p=0.041; OR=1.058, 95%CI 1.008-1.110, p=0.023, respectively).
Cardiac involvement especially myocarditis in SLE remains a rare but serious manifestation. Our research provided further insights into clinical features and risk factors of LM. Clinicians should be alerted for LM after cardiac manifestations occurred among those with SLE, which may reduce the risk of death.
本研究旨在探讨系统性红斑狼疮(SLE)合并心肌炎的临床特征和转归。
本研究为回顾性研究,纳入 2013 年 7 月至 2019 年 7 月在北京协和医院住院的 SLE 合并狼疮性心肌炎(LM)患者,设为病例组;另按照 1:1 年龄和年份匹配同期住院的无心肌炎的 SLE 患者为对照组。收集 LM 患者的临床特征和转归。
6 年间共 4719 例 SLE 患者住院,其中 79 例(1.67%)诊断为 LM,平均年龄为 32.38±13.55 岁,89%为女性。52 例(66%)患者存在心室壁运动异常,30 例(38%)患者超声心动图左心室射血分数(LVEF)<50%。住院期间 10 例(13%)LM 患者死亡。在心肌炎的危险因素方面,与对照组相比,LM 组患者神经系统受累比例更高,SLE 疾病活动指数 2000 评分(SLEDAI-2K)更高,抗核小体抗体阳性率更高。多因素 logistic 回归分析显示,补体 C3 水平降低和 SLEDAI-2K 评分升高是 SLE 患者发生 LM 的独立危险因素(OR=0.870,95%CI 0.762-0.994,p=0.041;OR=1.058,95%CI 1.008-1.110,p=0.023)。
心脏受累,尤其是 SLE 患者的心肌炎仍然是一种罕见但严重的表现。本研究进一步探讨了 LM 的临床特征和危险因素。当 SLE 患者出现心脏表现时,临床医生应警惕 LM 的发生,这可能降低死亡风险。